Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6117099 | 1.00 | KCNH2 (0.34) | KCNH2GRM5CYP1A2ARBRD4 | |
| SCHEMBL6117661 | 0.99 | KCNH2 (0.32) | KCNH2GRM5CYP1A2AR | |
| SCHEMBL6116344 | 0.96 | AR (0.32) | GRM5AR | |
| SCHEMBL6116940 | 0.93 | PTPN11 (0.31) | — | |
| SCHEMBL6117280 | 0.85 | KCNH2 (0.36) | KCNH2GRM5CYP1A2BRD4CREBBP | |
| SCHEMBL6116710 | 0.85 | KCNH2 (0.36) | KCNH2GRM5CYP1A2BRD4CREBBP | |
| SCHEMBL6115805 | 0.85 | CYP46A1 (0.34) | KCNH2GRM5CYP1A2 | |
| SCHEMBL6116769 | 0.85 | CYP46A1 (0.34) | KCNH2GRM5CYP1A2 | |
| SCHEMBL6117295 | 0.83 | CYP46A1 (0.34) | KCNH2GRM5CYP1A2AR | |
| SCHEMBL6116931 | 0.83 | KCNH2 (0.34) | KCNH2GRM5CYP1A2BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703969-B2 | Trifluoromethylthiophenium derivative salt, method for producing the same, and method for producing trifluoromethyl-containing compounds using the same | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2014-04-22 | — | — | US | disclosed |
| EP-2460802-A1 | TRIFLUOROMETHYLTHIOPHENIUM DERIVATIVE SALTS, PROCESS FOR PRODUCITON THEREOF, AND PROCESS FOR PRODUCTION OF TRIFLUOROMETHYL-CONTAINING COMPOUNDS USING SAME | Nagoya Institute of Technology (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120130090-A1 | TRIFLUOROMETHYLTHIOPHENIUM DERIVATIVE SALT, METHOD FOR PRODUCING THE SAME, AND METHOD FOR PRODUCING TRIFLUOROMETHYL-CONTAINING COMPOUNDS USING THE SAME | TOSOH F-TECH, INC. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130090-A1 | TRIFLUOROMETHYLTHIOPHENIUM DERIVATIVE SALT, METHOD FOR PRODUCING THE SAME, AND METHOD FOR PRODUCING TRIFLUOROMETHYL-CONTAINING COMPOUNDS USING THE SAME | TST, CBR3, CYP4B1 | KCNH2 550/4885GRM5 1759/4885CYP1A2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.